Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Spero Therapeutics, Inc.

We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for bacterial infections, including multi-drug resistant, or MDR, bacterial infections, and rare diseases. Spero’s lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Spero’s partnership directed programs consist of SPR206 and tebipenem HBr, which through the company’s business development efforts, have joint venture relationships supporting their ongoing development.  SPR206, is an IV-administered agent being developed as an innovative option to treat MDR Gram-negative bacterial infections, in the hospital setting.  Tebipenem HBr, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections, or cUTIs, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. 
 

We believe that our novel product candidates will have a meaningful impact on patient health and significant commercial applications for treating MDR infections in hospitals and community settings.

National Science Foundation

CARB-X

Biomedical Advanced Research and Development Authority (BARDA)

U.S. Department of Defense

HealthCare Royalty Partners

GlaxoSmithKline

Pfizer

Cowen Investment Management

OUP (Osage University Partners)

Rock Springs Capital

Lundbeckfonden Ventures

MRL Ventures Fund

Google Ventures

RA Capital Management

Spero Therapeutics

Today, we announced the first patient, first visit for PIVOT-PO, a global pivotal Phase 3 clinical trial of our potential novel therapy for those with complicated urinary tract infections (#cUTI) & acute pyelonephritis (AP). This may provide patients with an alternative treatment option to IV hospital therapy, which is the current standard of care. Read more about this important milestone here: https://brnw.ch/21wFKbu

#HappyNewYear! As we say farewell to 2023, #Sperobes are gearing up for a productive 2024, fueled by innovation and dedication to address the complexities of #RareDisease and #InfectiousDisease therapeutics, advancing standard of care for patients. Here's to another year of success.

As 2023 comes to a close, we're looking ahead to unfolding opportunities. In 2024, we're positioned to continue advancing our pipeline, focusing on incubating hope for patients with #InfectiousDiseases, including #MDR #BacterialInfections and nontuberculous mycobacterial (#NTMPD).

#HappyHolidays from our team to yours! We want to thank our #Sperobes, partnerships, and many others that have made our milestones of 2023 possible. Wishing everyone a relaxing and joyous holiday season!

Spero’s mission is to bring hope to patients living with #InfectiousDiseases and #RareDiseases. Our lead candidate has the potential to be the first novel oral antibiotic approved for the first-line treatment of #NTMPD, a rare #OrphanDisease. Learn more: https://brnw.ch/21wFd55

Living our core value to do good, #Sperobes helped serve hot meals at Rosie's Place. At Spero, our mission is to not only bring hope to those living with #InfectiousDiseases, but also give back to our greater community in Boston. Learn how you can support Rosie's place here: https://brnw.ch/21wEUsO

Wishing everyone a #HappyThanksgiving from all of us at Spero! We are thankful for #Sperobes and their dedication to our mission of developing novel therapies for #RareDiseases and #InfectiousDiseases.

Our #SpeakingSpero this month is our CMO, Kamal Hamed, MD, MPH, MBA. He has shared his thoughts on the current landscape of the #RareDisease and #InfectiousDisease space and what it's like to be a part of a team committed to developing impactful therapies to address unmet needs.

Join our President & CEO, Sath Shukla, for a fireside chat at the upcoming 6th Annual Evercore ISI #HealthCONx Conference on November 28, at 7:55 a.m. ET. Don't miss the opportunity to engage in one-on-one discussions with him as well. Secure your spot: https://lnkd.in/eycmwYVC

Today we shared our third quarter 2023 financial results in addition to upcoming milestones and updates on our pipeline of potential novel therapeutics for #RareDiseases and #InfectiousDiseases. Find more information here: https://brnw.ch/21wEpra

NASDAQ:SPRO

Spero Therapeutics

Last Close

1.37

30/08 20:00

Market Cap

73.42M

Beta: 0.87

Volume Today

58.38K

Avg: 603.93K

PE Ratio

−115.83

PFCF: 2.64

Financials Not Available